The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

Verona

Lungs illustration Image Pixabay
Biotech

Verona's COPD drug hits goal in phase 3, teeing up FDA filing

Verona has hit the mark in its first of two phase 3 COPD trials, keeping it on course to file for FDA approval of the inhaled PDE3 and PDE4 inhibitor.
Nick Paul Taylor Aug 9, 2022 6:40am
parachute jump

Frontier launches with biotech vet CEO—Chutes & Ladders

Jun 28, 2019 9:30am
contract

Verona hires ex-GSK researchers for late-phase push in COPD

Jun 25, 2019 8:10am
Lungs illustration Image Pixabay

Verona tanks after COPD drug misses phase 2 endpoint

Jan 14, 2019 9:25am
Research

Verona jumps as midphase cystic fibrosis data dial up hopes

Mar 2, 2018 9:25am
fda

Theravance COPD drug on track for FDA decision by November

Jan 29, 2018 11:15am